Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 76 peer-reviewed journal articles Updated
Allergy and Immunology

Validation and Orientation to HAE Type 1

At a Glance

Hereditary Angioedema (HAE) Type 1 is a rare genetic condition causing deep, painful swelling. Unlike allergies, HAE is driven by bradykinin, meaning standard allergy medications like EpiPens do not work. Modern preventative and rescue therapies allow patients to effectively control attacks.

Receiving a diagnosis of Hereditary Angioedema (HAE) Type 1 can feel like a heavy weight has finally been named. For many, this moment follows years of “unexplained” swelling, emergency room visits where allergy treatments failed, or even unnecessary surgeries [1][2]. It is completely normal to feel a mixture of relief, anxiety about the future, and overwhelm [3][4].

You are not alone in this journey, and while HAE is a lifelong condition, we are currently in an era of medicine where it is more manageable than ever before [5][6].

Understanding HAE Type 1

Hereditary Angioedema Type 1 is a rare genetic condition that affects approximately 1 in 50,000 people worldwide [7][4]. Because it is so rare, your local general practitioner or ER doctor may have never treated a case before; it is common for medical professionals to have significant “knowledge gaps” regarding HAE [8][9].

In plain language, your body is missing or low on a specific “stop switch” protein called C1-esterase inhibitor [10][11]. Without enough of this protein, your immune system accidentally releases too much of a chemical called bradykinin [12]. Think of bradykinin like a signal that tells your blood vessels to “leak” fluid into the surrounding tissue, which creates the deep, painful swelling you experience [12][13].

Why This Isn’t an Allergy

It is vital to understand that HAE is not an allergy. While the swelling might look like a typical allergic reaction (hives or “anaphylaxis”), the internal “engine” driving it is completely different.

  • Allergies are driven by histamine. They respond to EpiPens (epinephrine), Benadryl (antihistamines), and steroids [14].
  • HAE is driven by bradykinin. Because of this, standard allergy medications—including EpiPens—do not work to stop an HAE attack [14][8].

This distinction is why you may have felt frustrated in the past when emergency treatments didn’t seem to help your swelling.

Three Stabilizing Facts

When a diagnosis is new, it helps to ground yourself in what is known and controllable.

  1. Modern medicine is highly effective. We have moved past the era where patients simply had to “wait out” attacks. Modern prophylaxis (preventative treatment) and on-demand (rescue) therapies allow many patients to live nearly attack-free lives [15][16].
  2. You are the primary expert in your care. International guidelines now emphasize self-administration. This means you can be trained to give yourself your own medication at home or on the go, putting the power to stop an attack back in your own hands [16][17].
  3. Attacks are manageable with a plan. While the timing of an attack is unpredictable, the response to it shouldn’t be. By working with a specialist to create a written HAE Action Plan, you ensure that you and your medical team always know exactly what to do [18][19].

Navigating the Emotional Impact

The “unpredictability” of HAE is often the hardest part to carry. The anxiety of wondering when the next attack will happen, or if it will interfere with a major life event, is a recognized part of the disease [3][20]. Many patients experience higher levels of stress or depression because of this uncertainty [21][22].

Acknowledge these feelings as a valid response to a complex condition. As you gain control over the physical symptoms with the right treatment plan, the emotional burden often begins to lift [23][24]. Your goal is not just to “survive” attacks, but to reach a point of “total control” where HAE is a manageable part of your life rather than the center of it [5][6]. We highly recommend connecting with national or international patient advocacy groups, such as the US Hereditary Angioedema Association (HAEA) or HAE International (HAEi), for peer support and resources.

Explore This Guide

01

Symptoms, Triggers, and Common Misdiagnoses

Learn the key symptoms and triggers of Hereditary Angioedema (HAE) Type 1. Understand why GI attacks are often misdiagnosed and how HAE differs from allergies.

02

The Science: Bradykinin, C1-INH, and Genetics

Learn the science behind Hereditary Angioedema (HAE) Type 1. Understand SERPING1 gene mutations, bradykinin, and how to read your C4 and C1-INH lab results.

03

Modern Treatment: Prophylaxis and On-Demand Therapy

Discover modern treatments for Hereditary Angioedema Type 1 (HAE). Learn about long-term prophylaxis, on-demand rescue medications, and self-administration.

04

Navigating Medical Care and Emergencies

Learn how to manage Hereditary Angioedema (HAE) Type 1 emergencies. Discover how to build a care team, create an action plan, and self-administer treatments.

Common questions in this guide

Why doesn't an EpiPen work for my HAE swelling?
HAE swelling is caused by an overproduction of a chemical called bradykinin, not histamine. EpiPens and traditional allergy medications only work on histamine-driven allergic reactions, which is why they are completely ineffective for stopping an HAE attack.
What causes Hereditary Angioedema Type 1?
HAE Type 1 is a rare genetic condition where your body does not produce enough of a regulatory protein called C1-esterase inhibitor. Without enough of this protein, your immune system releases too much fluid into surrounding tissues, creating deep and painful swelling.
Can I treat an HAE attack at home?
Yes, modern medical guidelines highly recommend self-administration of HAE treatments. With proper training from your specialist, you can safely use on-demand rescue medications at home or on the go to stop an attack as soon as it begins.
Do I need to see a specialist for HAE Type 1?
Because HAE is very rare, many general practitioners or emergency room doctors have limited experience with it. It is highly recommended to seek care from a regional HAE specialist or an immunologist who is fully trained in modern HAE protocols and treatments.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do you have specific experience managing HAE Type 1, or should I be referred to a regional HAE specialist?
  2. 2.What is my current C1-esterase inhibitor level, and how does it confirm my Type 1 diagnosis?
  3. 3.Which acute (rescue) medication should I carry with me at all times, and can you train me to self-administer it?
  4. 4.Based on my history of attacks, am I a candidate for long-term prophylaxis to prevent attacks before they start?
  5. 5.Does this office have a 24-hour emergency contact who is familiar with HAE protocols if I have a laryngeal attack?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting.

    Zanichelli A, Longhurst HJ, Maurer M, et al.

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2016; (117(4)):394-398 doi:10.1016/j.anai.2016.08.014.

    PMID: 27742086
  2. 2

    National survey on clinical and genetic characteristics of patients with hereditary angioedema in Latvia.

    Kanepa A, Nartisa I, Rots D, et al.

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2023; (19(1)):28 doi:10.1186/s13223-023-00783-6.

    PMID: 37031173
  3. 3

    The current situation of hereditary angioedema patients in Germany: results of an online survey.

    Magerl M, Martinez-Saguer I, Schauf L, et al.

    Frontiers in medicine 2023; (10()):1274397 doi:10.3389/fmed.2023.1274397.

    PMID: 38288304
  4. 4

    Emerging drugs for the treatment of hereditary angioedema due to C1-inhibitor deficiency.

    Zanichelli A, Montinaro V, Triggiani M, et al.

    Expert opinion on emerging drugs 2022; (27(2)):103-110 doi:10.1080/14728214.2022.2105834.

    PMID: 35876094
  5. 5

    Therapeutic management of hereditary angioedema: past, present, and future.

    Valerieva A, Nedeva D, Yordanova V, et al.

    Balkan medical journal 2021; (38(2)):89-103 doi:10.5152/balkanmedj.2021.21094.

    PMID: 33724190
  6. 6

    A Treat-to-Target approach in hereditary angioedema: expert consensus from a European committee.

    Cancian M, Caballero T, Boccon-Gibod I, et al.

    Frontiers in immunology 2026; (17()):1773279 doi:10.3389/fimmu.2026.1773279.

    PMID: 41766887
  7. 7

    Hereditary angioedema: Pathophysiology (HAE type I, HAE type II, and HAE nC1-INH).

    Wedner HJ

    Allergy and asthma proceedings 2020; (41(Suppl 1)):S14-S17 doi:10.2500/aap.2020.41.200081.

    PMID: 33109319
  8. 8

    Hereditary angioedema: 24 years of experience in a Portuguese reference center.

    Varandas C, Esteves Caldeira L, Silva SL, et al.

    European annals of allergy and clinical immunology 2024; (56(5)):210-218 doi:10.23822/EurAnnACI.1764-1489.278.

    PMID: 36515257
  9. 9

    Impact of providing education on the recognition and differential diagnosis of angioedema among emergency department physicians.

    Unal D, Demir S, Işik SR, et al.

    The World Allergy Organization journal 2025; (18(8)):101101 doi:10.1016/j.waojou.2025.101101.

    PMID: 40822745
  10. 10

    Variability of disease activity in patients with hereditary angioedema type 1/2: longitudinal data from the Icatibant Outcome Survey.

    Maurer M, Caballero T, Aberer W, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2021; (35(12)):2421-2430 doi:10.1111/jdv.17654.

    PMID: 34506666
  11. 11

    HAE Pathophysiology and Underlying Mechanisms.

    Zuraw BL, Christiansen SC

    Clinical reviews in allergy & immunology 2016; (51(2)):216-29 doi:10.1007/s12016-016-8561-8.

    PMID: 27459852
  12. 12

    Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation.

    Petersen RS, Fijen LM, Levi M, Cohn DM

    Seminars in thrombosis and hemostasis 2024; (50(7)):978-988 doi:10.1055/s-0042-1758820.

    PMID: 36417927
  13. 13

    Bradykinin: Inflammatory Product of the Coagulation System.

    Hofman Z, de Maat S, Hack CE, Maas C

    Clinical reviews in allergy & immunology 2016; (51(2)):152-61 doi:10.1007/s12016-016-8540-0.

    PMID: 27122021
  14. 14

    Current and Emerging Therapeutics in Hereditary Angioedema.

    Do T, Riedl MA

    Immunology and allergy clinics of North America 2024; (44(3)):561-576 doi:10.1016/j.iac.2024.03.009.

    PMID: 38937016
  15. 15

    Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.

    Lumry WR, Weller K, Magerl M, et al.

    Allergy 2021; (76(4)):1188-1198 doi:10.1111/all.14680.

    PMID: 33258114
  16. 16

    Hereditary angioedema: an update on causes, manifestations and treatment.

    Longhurst HJ, Bork K

    British journal of hospital medicine (London, England : 2005) 2019; (80(7)):391-398 doi:10.12968/hmed.2019.80.7.391.

    PMID: 31283393
  17. 17

    Current medical management of hereditary angioedema: Follow-up survey of US physicians.

    Riedl MA, Banerji A, Gower R

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2021; (126(3)):264-272 doi:10.1016/j.anai.2020.10.009.

    PMID: 33122123
  18. 18

    Hereditary Angioedema in Pregnancy: A Case Report and Review of Obstetric Anesthesia Management.

    de Valle MK, Stevenson C, Adkison M, et al.

    A&A practice 2024; (18(9)):e01833 doi:10.1213/XAA.0000000000001833.

    PMID: 39248379
  19. 19

    Emergency Department Management of Hereditary Angioedema Attacks: Patient Perspectives.

    Otani IM, Christiansen SC, Busse P, et al.

    The journal of allergy and clinical immunology. In practice 2017; (5(1)):128-134.e4 doi:10.1016/j.jaip.2016.06.029.

    PMID: 27665386
  20. 20

    The relationship between anxiety and quality of life in children with hereditary angioedema.

    Kessel A, Farkas H, Kivity S, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2017; (28(7)):692-698 doi:10.1111/pai.12758.

    PMID: 28692169
  21. 21

    Quality of life and burden of disease in patients with hereditary angioedema and their caregivers.

    Levy DS, Nagase FI, Cheung A, et al.

    Allergy and asthma proceedings 2025; (46(5)):398-405 doi:10.2500/aap.2025.46.250048.

    PMID: 40958183
  22. 22

    Can depression and anxiety be predicted in hereditary angioedema? A comprehensive assessment.

    Akten HS, Dilek E, Orman M, Mete Gokmen EN

    Allergy and asthma proceedings 2025; (46(3)):e71-e81 doi:10.2500/aap.2025.46.250017.

    PMID: 40380370
  23. 23

    Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents.

    Craig T, Tachdjian R, Bernstein JA, et al.

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2024; (133(6)):712-719.e1 doi:10.1016/j.anai.2024.08.001.

    PMID: 39128590
  24. 24

    Patient Preferences for Long-Term Prophylactic Treatment in Hereditary Angioedema: A Discrete-Choice Experiment.

    Villa KF, Mansfield C, Yarlas A, et al.

    The patient 2026; (19(3)):481-495 doi:10.1007/s40271-025-00798-8.

    PMID: 41565919

This page provides general educational information about Hereditary Angioedema Type 1 and is not a substitute for professional medical advice. Always work directly with your HAE specialist to develop a personalized treatment and emergency action plan.

Get notified when new evidence is published on Hereditary angioedema type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.